And 3 months later...
There are plenty of examples of drugs being successful second to market. The point I was making is the expected revenues are much less. Look what 3-months did for PD1 inhibitors. For an already small OV market in melanoma, what do you think a 2nd place OV therapy will generate?
Seems I am doing more research into OV therapies than most of the people here. A lot of hope here - let the data tell the story.
Why IMU is a multi multi bagger, page-22297
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
-0.001(1.41%) |
Mkt cap ! $512.3M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.1¢ | 6.8¢ | $922.0K | 13.28M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 702419 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.1¢ | 1365317 | 9 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.0¢ |
Change
-0.001 ( 1.69 %) |
||||
| Open | High | Low | Volume | ||
| 7.0¢ | 7.1¢ | 6.8¢ | 5455105 | ||
| Last updated 15.59pm 24/05/2024 ? | |||||
| IMU (ASX) Chart |